<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Parry, Nicola</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Moasser, Mark M.</style></author><author><style face="normal" font="default" size="100%">Loibl, Sibylle</style></author><author><style face="normal" font="default" size="100%">Krop, Ian</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">Current Perspectives on HER2-Positive BC</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2014</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2014-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">17-18</style></pages><abstract><style  face="normal" font="default" size="100%">This article highlights some important features of HER2-positive breast cancer. These include a review of some of the molecular mechanisms implicated in tumorigenesis, how certain therapies are used to interfere with these processes, the benefits of neoadjuvant therapy, and the treatment of patients with metastatic disease.</style></abstract><number><style face="normal" font="default" size="100%">56</style></number><volume><style face="normal" font="default" size="100%">14</style></volume></record></records></xml>